NCT04143945View on ClinicalTrials.gov

A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

PHASE2CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

October 28, 2019

Primary Completion Date

January 4, 2020

Study Completion Date

January 4, 2020

Conditions
Healthy Volunteers Diabetes Mellitus, Type 2Healthy Volunteers OverweightHealthy Volunteers Obesity
Interventions
DRUG

Semaglutide (administered by DV3396 pen)

Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day

DRUG

Semaglutide (administered by PDS290 pen)

Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day

Trial Locations (1)

9728 NZ

Novo Nordisk Investigational Site, Groningen

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT04143945 - A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity | Biotech Hunter | Biotech Hunter